Hsbc Holdings PLC Sells 25,257 Shares of Fulgent Genetics, Inc. $FLGT

Posted by Brian Himes on Jul 2nd, 2026

Hsbc Holdings PLC lessened its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 32.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,056 shares of the company’s stock after selling 25,257 shares during the quarter. Hsbc Holdings PLC’s holdings in Fulgent Genetics were worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its stake in Fulgent Genetics by 69.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after purchasing an additional 548 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Fulgent Genetics in the 4th quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd lifted its position in Fulgent Genetics by 214.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after acquiring an additional 1,251 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in Fulgent Genetics in the 4th quarter valued at approximately $56,000. Finally, Raymond James Financial Inc. purchased a new stake in Fulgent Genetics during the 2nd quarter valued at $49,000. Institutional investors own 48.06% of the company’s stock.

Insider Buying and Selling at Fulgent Genetics

In other news, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $38,391.94. Following the completion of the sale, the chief operating officer directly owned 367,605 shares in the company, valued at $6,576,453.45. This represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the completion of the transaction, the insider directly owned 990,374 shares in the company, valued at approximately $17,717,790.86. This represents a 0.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,980 shares of company stock valued at $106,360 over the last 90 days. 36.18% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Piper Sandler reissued a “neutral” rating and issued a $15.00 target price (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $27.00.

Get Our Latest Stock Report on Fulgent Genetics

Fulgent Genetics Trading Up 1.5%

FLGT opened at $20.82 on Thursday. The firm’s 50 day simple moving average is $17.42 and its two-hundred day simple moving average is $20.25. The company has a market capitalization of $591.29 million, a PE ratio of -8.71 and a beta of 0.89. Fulgent Genetics, Inc. has a 1-year low of $13.46 and a 1-year high of $31.04.

Fulgent Genetics Company Profile

(Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.